AC IMMUNE PROVIDES TWELVE UPDATES ON ITS PIPELINE AT THE INTERNATIONAL CONFERENCE ON ALZHEIMER’S AND PARKINSON’S DISEASES

Lausanne, Switzerland, March 23, 2017 – AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company focused on neurodegenerative diseases, today announced that twelve updates on the advancement of its product and partnered product candidates and R&D programs will be provided/presented at the 13\textsuperscript{th} International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD\textsuperscript{TM} 2017). The conference is taking place in Vienna, Austria from March 29\textsuperscript{th} to April 2\textsuperscript{nd}, 2017.

<table>
<thead>
<tr>
<th>Program and Collaborator</th>
<th>Presentations and Timing</th>
</tr>
</thead>
</table>
| Crenezumab / Genentech   | ▪ Long term safety of crenezumab in an open-label extension of Phase 2 studies in mild-to-moderate AD  
  \textit{Poster – March 30}  
  ▪ Long term safety and tolerability of escalating doses of crenezumab in patients with mild-to-moderate Alzheimer’s disease  
  \textit{Oral Presentation – March 31 / 10:30-10:45}  
  ▪ Crenezumab’s preferential binding of oligomeric amyloid-beta species underlies its unique mechanism of action  
  \textit{Poster – April 1} |
| anti-Tau antibody / Genentech | ▪ A Phase 1 study to evaluate the safety and tolerability of RO7105705 in healthy volunteers and patients with mild-to-moderate AD  
  \textit{Poster – March 29}  
  ▪ Preclinical characterization, efficacy, pharmacokinetics and pharmacodynamics and safety of RO7105705 – an anti-Tau antibody currently in clinical development for AD  
  \textit{Oral presentation – March 29 / 10:00-10:15}  
  ▪ Chronic treatment with the murine surrogate of anti-Tau antibody RO7105705 reduces Tau pathology in a transgenic mouse model of tauopathy  
  \textit{Poster – March 29} |
| Tau-PET imaging agent / Piramal | ▪ First in human characterization of PI-2620, a next generation PET tracer for assessing tau in AD and other tauopathies  
  \textit{Poster – March 29}  
  ▪ Characterization of novel PET tracers for the assessment of Tau pathology in AD and other tauopathies  
  \textit{Oral presentation – March 31 / 16:15-16:30} |
| α-syn-PET imaging agent / Biogen | ▪ Novel PET Tracers of alpha-Synuclein for the diagnosis of Parkinson’s Disease  
  \textit{Oral presentation – March 31 / 16:30-16:45} |
Morphomer Tau

- Small molecules targeting Tau propagation demonstrate efficacy in an aggressive tauopathy mouse model
  Oral presentation – April 1 / 15:30-15:45

Tau spreading / École Polytechnique Fédérale de Lausanne (EPFL)

- The frequency of tau propagation from neuron to neuron is increased in mice carrying the amyloid pathology
  Poster – March 29

Abeta and Tau molecular profiling / Nestlé Institute of Health Sciences (NIHS)

- A new tool for the profiling of Tau and Abeta in AD
  Poster – March 29

Selected presentations and posters will be made available at the conclusion of the AD/PD™ 2017 Conference on AC Immune’s website under the section Science.

Forward looking statements

This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information—Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.

For further information please contact:

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Prof. Andrea Pfeifer</td>
<td>Eva Schier</td>
<td></td>
</tr>
<tr>
<td>Chief Executive Officer</td>
<td>Corporate Communications Manager</td>
<td></td>
</tr>
<tr>
<td>Phone: +41 21 345 91 21</td>
<td>Phone: +41 21 345 91 34</td>
<td></td>
</tr>
<tr>
<td>E-mail: <a href="mailto:andrea.pfeifer@acimmune.com">andrea.pfeifer@acimmune.com</a></td>
<td>Mobile: +41 79 926 66 03</td>
<td>E-mail: <a href="mailto:eva.schier@acimmune.com">eva.schier@acimmune.com</a></td>
</tr>
<tr>
<td>Nick Miles/Toomas Kull</td>
<td>In the US</td>
<td></td>
</tr>
<tr>
<td>Cabinet Privé de Conseils s.a.</td>
<td>Ted Agne</td>
<td></td>
</tr>
<tr>
<td>Phone: +41 22 321 45 40</td>
<td>The Communications Strategy Group Inc.</td>
<td></td>
</tr>
<tr>
<td>E-mail: <a href="mailto:miles@cpc-pr.com">miles@cpc-pr.com</a> <a href="mailto:kull@cpc-pr.com">kull@cpc-pr.com</a></td>
<td>Phone: +1 781 631 3117</td>
<td>E-mail: <a href="mailto:edagne@comstratgroup.com">edagne@comstratgroup.com</a></td>
</tr>
</tbody>
</table>